Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst - Blueprint Medicines ( NASDAQ:BPMC )

8 hours ago

JP Morgan initiated coverage on Blueprint Medicines Corporation BPMC, a biotech company focused on modulating immune mast cells. In 2023, the FDA approved Blueprint Medicines' Ayvakit ( avapritinib ) as the first, only treatment for indolent systemic mastocytosis ( ISM ) .

Ticker	Sentiment	Impact
BPMC	Bullish	70 %